Gruenenthal launches PhIII trials of neridronate for rare pain disorder
Gruenenthal has kicked off two pivotal Phase III trials investigating the bisphosphonate neridronate for the treatment of Complex Regional Pain Syndrome (CRPS).
Read More
Tag: Complex Regional Pain Syndrome
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
